ZA200708755B - Use of an epidermal growth factor receptor kinase inhibator (EGFR) in gefitinib resistant patients - Google Patents

Use of an epidermal growth factor receptor kinase inhibator (EGFR) in gefitinib resistant patients

Info

Publication number
ZA200708755B
ZA200708755B ZA200708755A ZA200708755A ZA200708755B ZA 200708755 B ZA200708755 B ZA 200708755B ZA 200708755 A ZA200708755 A ZA 200708755A ZA 200708755 A ZA200708755 A ZA 200708755A ZA 200708755 B ZA200708755 B ZA 200708755B
Authority
ZA
South Africa
Prior art keywords
inhibator
egfr
growth factor
factor receptor
epidermal growth
Prior art date
Application number
ZA200708755A
Other languages
English (en)
Inventor
Charles M Zacharchuk
Martins Harris Patricia
Lundberg Ante Bill
Susan E Quinn
Greenberger Lee
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ZA200708755B publication Critical patent/ZA200708755B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200708755A 2005-04-14 2007-10-12 Use of an epidermal growth factor receptor kinase inhibator (EGFR) in gefitinib resistant patients ZA200708755B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67128705P 2005-04-14 2005-04-14

Publications (1)

Publication Number Publication Date
ZA200708755B true ZA200708755B (en) 2008-10-29

Family

ID=36791648

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200708755A ZA200708755B (en) 2005-04-14 2007-10-12 Use of an epidermal growth factor receptor kinase inhibator (EGFR) in gefitinib resistant patients

Country Status (19)

Country Link
US (1) US20060235046A1 (xx)
EP (1) EP1871371A2 (xx)
JP (1) JP2008536847A (xx)
KR (1) KR20080002826A (xx)
CN (1) CN101160129A (xx)
AR (1) AR053357A1 (xx)
AU (1) AU2006236940A1 (xx)
BR (1) BRPI0610574A2 (xx)
CA (1) CA2646257A1 (xx)
CR (1) CR9415A (xx)
GT (1) GT200600146A (xx)
IL (1) IL186302A0 (xx)
MX (1) MX2007012662A (xx)
NO (1) NO20074722L (xx)
PE (1) PE20061396A1 (xx)
RU (1) RU2007134908A (xx)
TW (1) TW200718421A (xx)
WO (1) WO2006113151A2 (xx)
ZA (1) ZA200708755B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CA2725598C (en) 2008-06-17 2013-10-08 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
WO2010017163A1 (en) * 2008-08-04 2010-02-11 Wyeth Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
KR101341876B1 (ko) * 2008-09-05 2013-12-20 셀진 아빌로믹스 리서치, 인코포레이티드 비가역 인히비터 디자인을 위한 알고리즘
WO2010086382A1 (en) * 2009-01-30 2010-08-05 Pronota N.V. Target for treatment of acute heart failure
KR20140036332A (ko) 2009-04-06 2014-03-25 와이어쓰 엘엘씨 네라티닙을 이용한 유방암의 치료법
AU2010295690B2 (en) * 2009-09-16 2016-07-28 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
WO2011082285A1 (en) 2009-12-30 2011-07-07 Avila Therapeutics, Inc. Ligand-directed covalent modification of protein
CA2959208C (en) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
US9364469B1 (en) * 2015-08-26 2016-06-14 Macau University Of Science And Technology Identification of a new AMPK activator for treatment of lung cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
RU2006106267A (ru) * 2003-08-01 2006-07-27 Уайт Холдингз Корпорейшн (Us) Применение комбинации ингибитора киназы рецептора эпидермального фактора роста и цитотоксических средств для лечения и ингибирования рака
US7399865B2 (en) * 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
KR101289774B1 (ko) * 2004-03-31 2013-08-07 다나-파버 캔서 인스티튜트 인크. 표피성장인자 수용체를 표적으로 하는 치료에 대한 암의반응성을 결정하는 방법
AU2006210572B2 (en) * 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer

Also Published As

Publication number Publication date
WO2006113151A3 (en) 2007-01-11
CA2646257A1 (en) 2006-10-26
MX2007012662A (es) 2008-04-04
BRPI0610574A2 (pt) 2010-07-06
CR9415A (es) 2008-01-21
KR20080002826A (ko) 2008-01-04
PE20061396A1 (es) 2007-01-12
WO2006113151A2 (en) 2006-10-26
AU2006236940A1 (en) 2006-10-26
GT200600146A (es) 2006-11-07
JP2008536847A (ja) 2008-09-11
AR053357A1 (es) 2007-05-02
NO20074722L (no) 2007-11-12
IL186302A0 (en) 2008-08-07
CN101160129A (zh) 2008-04-09
TW200718421A (en) 2007-05-16
EP1871371A2 (en) 2008-01-02
RU2007134908A (ru) 2009-05-20
US20060235046A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
ZA200708755B (en) Use of an epidermal growth factor receptor kinase inhibator (EGFR) in gefitinib resistant patients
IL281715A (en) Activin-ActrIIA antagonists and their use to increase bone growth in cancer patients
IL185210A0 (en) Epidermal growth factor receptor mutations
HK1248598A1 (zh) Activin-actriia拮抗劑及其促進骨骼生長的應用
LTC1735348I2 (lt) Antikūnas prieš žmogaus epiderminio augimo faktoriaus receptorių
IL182584A0 (en) Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
ZA200609427B (en) Quinazoline derivatives as erbB receptor tyrosine kinases
IL186139A0 (en) Epidermal growth factor receptor gene copy number
AP2007003924A0 (en) Imidazopyrazine as tyrosine kinase inhibitors
IL182525A0 (en) Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
ZA201004603B (en) 3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mtor kinase and p13 kinase inhibitors, and their synthesis
GB0426767D0 (en) Surgical instrument
ZA200702877B (en) Quinazoline derivatives
HK1095590A1 (en) Quinazoline derivatives
EP1735461A4 (en) ORPHANIC RECEPTOR TYROSINE KINASE AS A TARGET IN BREAST CANCER
HK1085400A1 (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
IL197157A0 (en) Method for evaluating patients for treatment with drugs targeting ret receptor tyrosine kinase
IL180256A0 (en) Pyrido-pyrido pyrimidine derivatives, preparation thereof, therapeutic use thereof for treating cancer
EP1806147A4 (en) USE OF IMMUNOSUPPRESSIVE RECEPTOR
HK1120793A1 (en) 4- (ih-indazol-5-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
IL184798A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
SI1660090T1 (sl) Kinazolinski analogi kot inhibitorji receptorjev tirozin kinaze
EP1832299A4 (en) MEDICAMENT AGAINST HEART DISEASE INCLUDING TNNI3K MAP-KINASE
GB0403363D0 (en) Surgical instrument
EP1773367A4 (en) RECEPTOR ANTAGONISTS FOR EPIDERMAL GROWTH FACTOR AND USE METHOD